Stentit’s CEO on Regenerating Arteries with Biodegradable Stents скачать в хорошем качестве

Stentit’s CEO on Regenerating Arteries with Biodegradable Stents

In this exclusive MedTech World interview, Bart Sanders, CEO and founder of STENTiT, shares how his team is pioneering a first-of-its-kind regenerative stent that transforms into a living artery. Based in the Netherlands, STENTiT is tackling critical limb-threatening ischemia (CLTI) — a severe form of peripheral artery disease (PAD) — by using bioresorbable nanofibers that trigger natural healing. Their groundbreaking device allows immune cells to reconstruct functional tissue within just 3 months, potentially avoiding amputations and offering long-term vascular health. With CE mark and FDA trials underway, STENTiT is seeking Series A investment to expand its clinical reach across the EU and US. Learn how this Dutch MedTech innovator plans to reshape vascular treatment — from limb ischemia to aneurysm care. 🔗 Subscribe for more MedTech innovation stories 📩 Connect with STENTiT for investment or collaboration